ARTICLE | Company News
FDA to review NPS's Natpara
January 9, 2014 2:08 AM UTC
FDA accepted for review a BLA from NPS Pharmaceuticals Inc. (NASDAQ:NPSP) for Natpara to treat hypoparathyroidism. The PDUFA date is October 24. The product is a recombinant human parathyroid hormone ...